Literature DB >> 26239272

Enrichment and characterization of cancer stem cells from a human non-small cell lung cancer cell line.

Changhong Zhao1, Sarra Setrerrahmane1, Hanmei Xu1.   

Abstract

Tumor cells from the same origin comprise different cell populations. Among them, cancer stem cells (CSCs) have higher tumorigenicity. It is necessary to enrich CSCs to determine an effective way to suppress and eliminate them. In the present study, using the non-adhesive culture system, tumor spheres were successfully generated from human A549 non-small cell lung cancer (NSCLC) cell line within 2 weeks. Compared to A549 adherent cells, sphere cells had a higher self-renewal ability and increased resistance to cytotoxic drugs. Sphere cells were more invasive and expressed stem cell markers including octamer‑binding transcription factor 4 (Oct4) and sex-determining region Y-box 2 (Sox2) at high levels. CD133, a disputed marker of lung CSCs, was also upregulated. Tumor sphere cells showed higher tumorigenic ability in vivo, indicating that more CSCs were enriched in the sphere cells. More blood vessels were formed in the tumor generated by sphere cells suggesting the interaction between CSCs and blood vessel. A reliable model of enriching CSCs from the human A549 NSCLC cell line was established that was simple and cost-effective compared to other methods.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 26239272     DOI: 10.3892/or.2015.4163

Source DB:  PubMed          Journal:  Oncol Rep        ISSN: 1021-335X            Impact factor:   3.906


  8 in total

1.  3D Tumor Spheroid Models for In Vitro Therapeutic Screening of Nanoparticles.

Authors:  Simonas Daunys; Agnė Janonienė; Indrė Januškevičienė; Miglė Paškevičiūtė; Vilma Petrikaitė
Journal:  Adv Exp Med Biol       Date:  2021       Impact factor: 2.622

2.  microRNA-301b-3p downregulation underlies a novel inhibitory role of long non-coding RNA MBNL1-AS1 in non-small cell lung cancer.

Authors:  Peng Li; Wenqun Xing; Jinliang Xu; Dongfeng Yuan; Guanghui Liang; Baoxing Liu; Haibo Ma
Journal:  Stem Cell Res Ther       Date:  2019-05-21       Impact factor: 6.832

Review 3.  Modulation of Immune Components on Stem Cell and Dormancy in Cancer.

Authors:  Xiaofan Jiang; Lu Liang; Guanglei Chen; Caigang Liu
Journal:  Cells       Date:  2021-10-21       Impact factor: 6.600

4.  AMP-activated protein kinase promotes breast cancer stemness and drug resistance.

Authors:  Sai Balaji Andugulapati; Ananthalakshmy Sundararaman; Mohini Lahiry; Annapoorni Rangarajan
Journal:  Dis Model Mech       Date:  2022-05-27       Impact factor: 5.732

5.  Enhanced therapeutic effect of an antiangiogenesis peptide on lung cancer in vivo combined with salmonella VNP20009 carrying a Sox2 shRNA construct.

Authors:  Changhong Zhao; Junjin He; Haoran Cheng; Zhaohao Zhu; Hanmei Xu
Journal:  J Exp Clin Cancer Res       Date:  2016-07-02

Review 6.  Cancer Stem Cells-Origins and Biomarkers: Perspectives for Targeted Personalized Therapies.

Authors:  Lia Walcher; Ann-Kathrin Kistenmacher; Huizhen Suo; Reni Kitte; Sarah Dluczek; Alexander Strauß; André-René Blaudszun; Tetyana Yevsa; Stephan Fricke; Uta Kossatz-Boehlert
Journal:  Front Immunol       Date:  2020-08-07       Impact factor: 7.561

Review 7.  Impact of Cancer Stem Cells and Cancer Stem Cell-Driven Drug Resiliency in Lung Tumor: Options in Sight.

Authors:  Lourdes Cortes-Dericks; Domenico Galetta
Journal:  Cancers (Basel)       Date:  2022-01-06       Impact factor: 6.639

Review 8.  Biomedical Applications of Non-Small Cell Lung Cancer Spheroids.

Authors:  Julian M Rozenberg; Gleb I Filkov; Alexander V Trofimenko; Evgeny A Karpulevich; Vladimir D Parshin; Valery V Royuk; Marina I Sekacheva; Mikhail O Durymanov
Journal:  Front Oncol       Date:  2021-12-07       Impact factor: 6.244

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.